Genetic variation in the Middle East—an opportunity to advance the human genetics field
Ahmad N. Abou Tayoun 1,2* and Heidi L. Rehm 3,4,5*

Abstract
We highlight the current lack of representation of the Middle East from large genomic studies and emphasize the expected high impact of cataloging its variation. We discuss the limiting factors and possible solutions to generating and accessing research and clinical sequencing data from this part of the world.

Genomic diversity in large-scale sequencing efforts and persistent bias
In a series of landmark articles, the largest sequenced human cohort representing a diverse group of individuals from across the world has been characterized. The Genome Aggregation Database (gnomAD) represents aggregated and uniformly processed whole genome (n = 15,708) and exome (n = 125,748) sequencing data to catalog genetic variation across coding and noncoding regions of the human genome [1, 2]. The dataset, which now includes structural variants (SVs), as well as 241 million small variants, empowers researchers to estimate gene tolerance to variation in an unprecedented way, and aids in the clinical interpretation of genome variation [1, 2].

One of the main strengths of the gnomAD database, and its predecessor, the Exome Aggregation Consortium (ExAC) database [3], lies in capturing sequencing data representing diverse European and non-European ancestries at a larger scale compared to previous sequencing studies [4]. Around 43% of individuals in the gnomAD database are non-European Asians (10.8% South Asians and 7% East Asians), Latino (12.5%), Ashkenazi Jewish (3.7%), and Africans or African Americans (8.8%) (Fig. 1). This represents a major shift from the existing significant bias in most large-scale genomic studies, where the majority of individuals have been mostly of European origin, raising legitimate concerns that precision or genomic medicine will be a privilege for the “few” represented in those studies. As of June 14, 2020, 88.5% of genome-wide association studies (GWAS)—summarized in the GWAS Catalog (www.ebi.ac.uk/gwas), produced by the US National Human Genome Research Institute and the European Bioinformatics Institute, and recently monitored through the GWAS Diversity Monitor (www.gwasdiversitymonitor.com) [5]—were Europeans while only 7.5% were Asians and 4% Africans, Latin, and among few others (Fig. 1). Thus, gnomAD is an important step towards, a very much needed, broader genetic representation.

However, despite its size, the gnomAD dataset captures only 3.7 and 11.5% of all possible nonsense and synonymous variants, respectively, across all mutational contexts [1], thus falling short on identifying the full mutational spectrum of the coding regions. Increasing cohort size as well as further diversifying the genomic data to include individuals of unrepresented ancestries can help in this regard. While there has been progress in the growth of data across a number of ancestries, gnomAD authors correctly point out, this cohort has an almost complete absence of representation from certain
Fig. 1 (See legend on next page.)
groups, mainly Oceania, Southeast Asia, much of Africa, and the Middle East [1]. Among these, Arabs of the Middle East, geographically spanning North Africa, the Arabian Peninsula, and the Syrian desert, have a rich history of migration and admixture with Africans, Europeans, Persians, Turks, and Southeast Asians. Besides Arabs, this region is also home for other minorities including Jews, Armenians, and Kurds.

**Missed opportunities in Arab genomes**

In addition to genetic diversity, the Arab family is characterized by its large size, high matriliney and paternity ages at conception and significant endogamy with consanguinity rates between 25 and 60% which are 100-fold higher than the < 0.2% consanguinity rate in Western countries [6]. Therefore, it is expected that Arab genomes have a high burden of regions of homozygosity (ROH) leading to a higher incidence of Mendelian recessive disorders [6].

From a population genomics standpoint, the extended ROH regions can be enriched for two-hit gene knockouts (homozygous loss of function, LoF, variants), in apparently “healthy” individuals, providing opportunities to understand the biological roles of several genes which cannot be encountered in outbred populations, like most data in gnomAD. Of 125,748 exomes in gnomAD v2.1, authors identified only 1815 genes with at least one LoF variants from individuals of the Greater Middle East [6], Pakistan [7], and gnomAD v2.1 [1]. Circle size correlates with a fraction of the number of KO in a given sample size. F = coefficient of inbreeding.

Even if sequencing data from both the GME study mentioned above and the gnomAD v2.1 dataset were combined, this highly diverse region will represent less than 1% of all publicly accessible sequencing datasets (Fig. 1). This underrepresentation might be attributed to several factors which have to be addressed if we are to fully harvest genomic variation in the Middle East, which will in turn further our understanding of genetic diseases.

**Roadblocks in genomic sequencing in the Middle East**

A major factor limiting genomic studies is the lack of comprehensive educational and awareness genetics programs in most Middle Eastern countries. Such programs are needed at every level to address cultural, legal, public health, and training issues associated with genomic investigations. There are societal stigmas attached to genetic diseases, discouraging families from pursuing any research or clinical genetic investigations. Trained genetic counselors, who are familiar with local traditions, are currently lacking but desperately needed to mitigate the stigmas surrounding genetics. Healthcare professionals are urged to educate decision-makers about the long-term societal and economic burdens of genetic diseases, so as to invest in establishing relevant genomic research and training programs in those countries.
Outcomes of such programs include training local professionals in genomics, and building the genetic evidence to guide public health efforts, including national genetic screening programs, to be implemented in healthcare systems. Those efforts will eventually promote the implementation of genomic medicine, will better educate the public about genetics, and will lead to the proliferation of sequencing datasets to support research in this field.

Another limiting factor is obviously the lack of resources to enroll genomics into long-term research and healthcare agendas. Several countries in the Middle East are devastated by political tensions, economic crises, and regional or local conflicts. Under such circumstances, resources are inevitably allocated to other basic priorities leaving behind no room for investments in genomics, and hardly any relevant human resources. For some of those countries, a short-term solution might include collaborative projects with external investigators and institutions where funding agencies would encourage ascertainment of participants from the Middle East for genomic sequencing studies.

Given the above roadblocks, genomic studies are limited to very few laboratories—in a few countries—where sequencing data exist in silos, and are not broadly shared, most likely due to existing stigmas and regulatory restrictions around genetic data, which end up hampering the research consent process. One goal of the educational programs discussed above would be to encourage the public, researchers, and legislators to broadly share genetic data nationally and internationally with the common ultimate goal of advancing the human genetics field, and expanding our knowledge of genetic diseases. Failing to do so risks the national interests of any country by depriving its residents of the long term advances in genomics.

Finally, outside the Middle East, it is important to distinguish “Arabs” from “White” ancestries, as is currently considered by the US Government Consensus. This might lead to better representation of “Arabs,” given the US efforts to enhance the representation of “minorities” in genomic databases.

Conclusions

Broadly unlocking the Middle Eastern Arab—and other minority—genomes promises to advance human genetics research, and bolster precise genomic diagnostics and therapeutics. It is encouraging that national genome projects started developing in the Gulf region (Kuwait, Qatar, Saudi Arabia) which will hopefully expand to other countries and lead to sharing broader and more representative genetic data from the Middle East. We all share most of the human genome sequence, and we can only understand it better if we collectively share our diverse genetic variation.

Acknowledgements

We would like to thank Sathishkumar Ramaswamy, from Al Jalila Genomics Center, for his help with the data from GWAS diversity monitor.

Authors’ contributions

Both authors drafted and edited the manuscript and also approved the final version.

Funding

None

Competing interests

Rehm declares a pending NIH grant from the National Human Genome Research Institute to support gnomAD. The remaining author declares that he has no competing interests.

Author details

1 Al Jalila Genomics Center, Al Jalila Children’s Hospital, Dubai, United Arab Emirates. 2 College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates. 3 Medical & Population Genetics Program and Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. 4 Department of Pathology, Harvard Medical School, Boston, MA 02115, USA. 5 Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Received: 2 September 2020 Accepted: 9 December 2020

Published online: 28 December 2020

References

1. Karczewski KJ, Francioli LC, Tao Q, Cummings BB, Alfoldi J, Wang Q, et al. The mutational constraint spectrum from variation in 141,456 humans. Nature. 2020;581:43–43.
2. Minikel EV, Karczewski KJ, Martin HC, Cummings BB, Whiffin N, Rhodes D, et al. Evaluating drug targets through human loss-of-function genetic variation. Nature. 2020;581:459–64.
3. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Bans E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,606 humans. Nature. 2016;536:285–91.
4. Fu W, O’Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature. 2013;493:216–20.
5. Mills MC, Rahai C. The GWAS diversity monitor tracks diversity by disease in real time. Nat Genet. 2020;52:242–3.
6. Scott EM, Halees A, Istan Y, Spencer EG, He Y, Azab MA, et al. Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. Nat Genet. 2016;52:1071–6.
7. Saleheen D, Natarajan P, Armean IM, Zhao W, Rasheed A, Khetarpal SA, et al. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature. 2017;544:235–9.
8. Alsaalem AB, Halees AS, Anazi S, Alshamiekh S, Alkuraya FS. Autozygome sequencing expands the horizon of human knockout research and provides novel insights into human phenotypic variation. PLoS Genet. 2013(9);12:e1004030.
9. Sharmia A, Shaheen R, Sabbagh N, Almoisheer A, Halees A, Alkuraya FS. Revisiting disease genes based on whole-exome sequencing in consanguineous populations. Hum Genet. 2015;134;1029–34.
10. Abouelhoda M, Faquih T, El-Kalioby M, Alkuraya FS. Revisiting the morbid genome of Mendelian disorders. Genome Biol. 2016;17:235.